Across 104 VAs, the PSA screening rate among men with limited life expectancy ranged from 25-79% (median 43%). Higher screening was associated with the following center characteristics: no academic affiliation (50% vs. 43%, adjusted RR=1.14, 95% CI 1.04-1.25), a ratio of midlevel providers to physicians ≥3:4 (55% vs. 45%, adjusted RR = 1.20, 95% CI 1.09-1.32) and location in the South (49% vs. 39% in the West, adjusted RR=1.25, 95% CI 1.12-1.40). Use of incentives and high scores on performance measures were not independently associated with screening. Within centers, the percentages of men screened with limited and favorable life expectancies were highly correlated (r=0.90). CONCLUSIONS: Substantial practice variation exists for PSA screening in older men with limited life expectancy across VAs. The high center-specific correlation of screening among men with limited and favorable life expectancies indicates that PSA screening is poorly targeted according to life expectancy.
INTRODUCTION
Guidelines from the U.S. Preventive Services Task Force (USPSTF), American Cancer Society, and American Urologic Association all recommend against prostatespecific antigen (PSA) screening in elderly men with limited life expectancy. [1] [2] [3] Most screen-detected prostate cancers will not cause symptoms for many years. Thus, men with limited life expectancy have little chance of experiencing benefits from screening, which occur years in the future, yet are at high risk of experiencing immediate burdens, including unnecessary biopsies, as well as incontinence, impotence, proctitis, hot flashes, and other adverse effects from treatment of clinically inconsequential cancers. [3] [4] [5] Prior studies have shown substantial PSA screening among American men aged 80 and older, although regional screening rates range from under 2% to 56%. [6] [7] [8] [9] [10] [11] Within the VA, 45% of men over 80 received PSA screening in 2003. 7 High rates of screening in elderly men are also common in fee-for-service Medicare, especially in regions with higher expenditures, more intensive end-of-life care, more unique physicians seen, and greater use of specialists for ambulatory care. 9 While studies have demonstrated geographic variation in PSA screening of elderly men across large hospital referral regions, 9 we are unaware of studies examining variation at the level of the medical center, which is a key locus for implementing screening policies. Furthermore, we are unaware of studies of geographic variation focusing on elderly men with limited life expectancy.
To characterize variation in PSA screening of older men across VA medical centers according to life expectancy, we examined VA data and Medicare claims for men aged 70 and older seen at 104 VAs. We identified patient and medical center characteristics prior to 2003 and calculated the percent of men who received PSA screening at each center in 2003. We aimed to identify medical center characteristics associated with higher PSA screening among elderly men with limited life expectancy, in order to guide interventions to reduce screening in men for whom potential burdens outweigh potential benefits.
METHODS

Data Sources and Patients
We identified a cohort of screen-eligible men aged 70 and older on 10/1/02, following them through 9/30/03 (FY 2003) for receipt of PSA screening; hereafter all years refer to fiscal years. Men were assigned to the VA that ordered their first PSA test in 2003; if they were not screened, they were assigned to the center where they had the most outpatient visits in 2003. Data were collected from the VA National Data Systems, the central repository for VA data, including the National Patient Care Database (inpatient/ outpatient VA claims), fee basis files (claims for non-VA services paid by the VA), and 2003 VA Decision Support System National Data Extracts Laboratory Results Data Set (lab results including PSA, available for 104 of 127 VAs). 7 We used linked Medicare claims from the VA Information Resource Center to identify non-VA services paid by Medicare in our cohort.
From these data sources, we identified 1,086,397 men aged 70 or older with at least one outpatient visit in both 2002 and 2003 at one of 104 VAs. After applying exclusions shown in Figure 1 , 622,262 men remained in our screen-eligible cohort, seen at 104 VAs across the U.S.
Data Collection and Measurement
Outcome Variable. We assessed receipt of PSA screening during 2003 across the VA system and Medicare. Screening within the VA was defined by an outpatient PSA in the 2003 VA Decision Support System National Data Extracts Laboratory Results Data Set. Completeness of extraction was confirmed by comparing our data with an independently extracted VA Decision Support System Laboratory Data Set. 7 We also assessed PSA screening reimbursed by Medicare, since most VA users over age 65 are also enrolled in Medicare and may be screened in the community through Medicare. PSA screening reimbursed by Medicare was identified by Current Procedure Terminology (CPT) codes G0103 and 84153 from hospital outpatient records and physician/supplier files for each patient. 12 Predictor Variables. Medical center characteristics hypothesized to influence PSA screening were obtained from the 1999-2000 VA Survey of Primary Care Practices, completed by primary care directors at 100 of 104 VAs, 13, 14 and publicly available VA data. 15, 16 Center characteristics obtained from the survey included 1) academic affiliationformal arrangement with an academic training program for medical residents; 2) initial primary care clinic appointment length ≥45 minutes-greater than average time allotted for new patient appointments; 3) primary care geriatricianshaving geriatricians providing primary care or direct primary care supervision; 4) ratio of midlevel providers [nurse practitioners (NP) and physician assistants (PA)] to physicians (MD) in primary care ≥3:4-a ratio of full-time equivalents for NP + PA/MD in the upper quartile of VAs; and 5) incentives for achieving primary care performance measures-awards (e.g., plaques, certificates) or monetary incentives (e.g., bonuses) for high primary care performance. Publicly available reports from the VA Office of Quality and Performance provided each VA's 2003 performance scores on prostate cancer screening education (i.e., chart documentation of discussion of pros/cons of prostate cancer screening for men aged 50-69) and colorectal cancer screening (i.e., performance of timely colorectal cancer screening for patients in primary care). 16 Medical center scores were dichotomized at the median and reflect targets for satisfactory performance. Additionally, the 2003 VA and DoD Healthcare Facilities Directory provided total reported healthcare expenditures and number of outpatient visits at each center in 2002, presented as tertiles. 15 Medical center size was based on the number of men each center contributed to our cohort. Region within the U.S. was categorized into Midwest, Northeast, South, and West based on criteria from the 2000 U.S. Census.
Patient characteristics measured included age at the start of 2003 and comorbidity defined by the Deyo adaptation of the Charlson Comorbidity Index. 17 Charlson scores were calculated from VA and Medicare inpatient/outpatient claims during 12 months prior to 2003. Men were categorized into three mutually exclusive groups based on life expectancy: 1) "favorable" life expectancy for those aged 70-79 with Charlson score=0; 2) "limited" life expectancy for those aged 85 and older with Charlson score ≥1, or those aged 70 and older with Charlson score ≥4; and 3) everyone else. These categories identify one group with favorable life expectancy (> 10 years) for whom several guidelines recommend offering PSA screening, and another group (life expectancy ≤5 years) that all guidelines agree is unlikely to benefit from screening. 18, 19 Other patient characteristics known to influence cancer screening included race/ethnicity and marital status, ascertained from VA and Medicare data. We also used linkages to the 2000 U.S. Census to determine for each veteran's ZIP code area the percentage of adults with a college education and the median income for adults aged 65 and older.
The Committee on Human Research at the University of California, San Francisco and the Committee for Research and Development at the San Francisco VA approved the study.
Statistical Analysis
The percentage of men who received PSA screening in 2003 was determined for each VA. We also determined the percentages of men with favorable and limited life expectancies who received PSA screening, to determine how well screening is targeted according to life expectancy. A Pearson correlation coefficient was calculated to describe the relationship between screening rates in men with limited and favorable life expectancies. For men with limited life expectancy, the associations between medical center/patient characteristics and receipt of PSA screening were determined by log-Poisson regression models with fixed effects for medical center/patient characteristics and random effects for medical centers. We used log-Poisson models to estimate unadjusted and adjusted risk ratios and 95% confidence intervals. 20 The ratio of midlevel providers to physicians was missing at 10% of sites, so missing values were multiply imputed using five rounds of imputation. 21 SAS procedures MI and MIANALYZE were used to generate and analyze multiply imputed datasets. Risk ratios for bivariate associations were reported using complete cases, and adjusted risk ratios were calculated using imputed data. Additionally, a sensitivity analysis was performed excluding men whose first PSA test in 2003 was through Medicare to focus solely on screening within the VA. All analyses were performed using SAS® version 9.2 and Stata version 10 statistical software packages.
RESULTS
Baseline Characteristics
Characteristics of the 622,262 elderly men in our cohort are presented in Table 1 . 69% received care at a medical center with formal academic affiliation; 53% at a center with primary care performance incentives; 15% at a center in the West; and 11% at a center where the ratio of midlevel providers to physicians was ≥3:4. of men who received screening at each center ranged from 33-87%, illustrating wide variation in screening practices at VAs across the U.S. (Figure 2 ). The percentage of men with limited life expectancy who received PSA screening was somewhat lower at 45% and also varied substantially across centers, ranging from 25-79%. 31% (32/104) of centers screened over half of men with limited life expectancy. VAs with the highest overall screening (Centers A-E) had high screening in men with both limited and favorable life expectancies. Screening rates among men with limited and favorable life expectancies were highly correlated (r=0.90) (Figure 3 ).
PSA Screening Rates
Medical Center and Patient Factors Associated with PSA Screening
The percentage of men with limited life expectancy who received PSA screening is presented by medical center/ patient characteristics in Table 2 . Center characteristics associated with higher screening in men with limited life expectancy included having no academic affiliation (50% vs. 43%, adjusted RR=1.14, 95% CI 1.04-1.25), having a ratio of midlevel providers to physicians in primary care ≥3:4 (55% vs. 45%, adjusted RR=1.20, 95% CI 1.09-1.32), and location in the South (49% vs. 39% in the West, (Table 2) . Primary care performance incentives were associated with higher screening in bivariate analyses but not in adjusted analyses. Among men with limited life expectancy, several patient characteristics were associated with PSA screening. White men were 20% more likely to be screened than black men. Men who were younger, married, and had higher socioeconomic status were also more likely to be screened (Table 2 ).
To rule out that variation in PSA screening across centers was driven by community screening, we performed a sensitivity analysis including only PSA tests within the VA; all associations remained the same. Overall, 40% of men in our cohort received PSA screening within the VA and 14% within Medicare. Using VA data alone, percentages of men screened at each center ranged from 18-85%, indicating that variation was not driven by Medicare testing.
DISCUSSION
Despite long-standing guidelines recommending against PSA screening in elderly men with life expectancy less than 10 years, [1] [2] [3] we found high screening in this population with substantial variation across VAs. Nearly one-third of medical centers screened more than half of men with limited life expectancy. VAs in the South, without academic affiliation, and with a high ratio of midlevel providers to physicians in primary care screened the most men with limited life expectancy, even after adjusting for patient characteristics. Additionally, at each VA the percentages of men screened with limited and favorable life expectancies were highly correlated, indicating that screening is being poorly targeted.
There is growing literature examining regional variation in cancer screening, although it has rarely assessed variation according to life expectancy. The literature examining PSA screening in the U.S. has described screening of older men based on age cut-offs without consideration of comorbidity, showing wide variations by region. 6, [9] [10] [11] Using national surveys or Medicare claims, studies have found that Southern regions screen at higher rates, and describe twofold to 20-fold regional variations in the percentage of older men screened. 6, 9, 22, 23 Similarly, we found that VAs in the South screen at higher rates than in the West, including for men with limited life expectancy. Even across the nationally integrated VA system, we found threefold differences in screening of men with limited life expectancy. One VA in the Midwest screened nearly 80% of this population. Possible explanations for differences include regional physician attitudes about resource allocation 24 -with the South and Midwest generally having high healthcare expenditures, 25 beliefs about the effectiveness of PSA screening, 26, 27 or regional patient preferences for screening. 28 Studies outside the VA suggest the latter is less likely. 10, 24, 28 In addition to region, other center characteristics associated with high PSA screening of men with limited life expectancy include lack of academic affiliation and a high ratio of midlevel providers (NPs and PAs) to physicians in primary care. The negative association of academic affiliation with PSA screening has been found previously [29] [30] [31] and explained by a greater emphasis of evidence-based medicine at academic centers, although there is substantial variation in PSA knowledge and practices even within a single center. 26, 29, 32 Furthermore, prior studies suggest a weaker malpractice climate in academic settings may lead to less defensive medicine. 27, 29, 33 The evidence is less consistent regarding the role of midlevel providers in screening. 34, 35 Studies show increased colorectal cancer screening with higher use of NPs and PAs, 35 and decreased PSA screening of men aged 75 and older. 36 Although the latter *Adjusted for all characteristics in Table 2 study appears to conflict with our results, the difference might be explained by the fact that the study utilized provider-level data, while we examined data at the level of the medical center. A high ratio of midlevel providers to physicians at a medical center may be more indicative of tight hospital resources or high patient load, rather than screening practices of individual providers. Incentives for primary care performance and scores on prostate cancer screening education did not significantly affect PSA screening practices. These programs have been criticized by some as encouraging a one-size-fits-all approach to care. 37, 38 We found that medical centers are uniformly not targeting screening according to life expectancy, regardless of performance measures or whether a center has a high or low overall screening rate. Not only do high screening VAs screen many men with limited life expectancy who should not be screened, but centers screening few men with limited life expectancy also screen few men with favorable life expectancy, for whom some guidelines recommend screening. One explanation for poor targeting at low screening centers may be an overall attitude that PSA is a poor test that causes more harm than good, which is a position now supported by 2011 USPSTF guidelines. 24, 27, 39, 40 Although we found only a few center characteristics associated with PSA screening in men with limited life expectancy, this does not suggest that individual VA culture and policies do not influence screening. 41 While we did not measure medical center screening policies in this study, we did speak with the Quality Assurance Coordinator for Primary Care at the highest screening VA (Site A) and learned that PSA is included in the annual wellness labs for all men. This decision has contributed to a very high rate of PSA screening (79%) among elderly men with limited life expectancy at this VA. Meanwhile, one of the lowest screening sites (Site I) is only 300 miles from Site A. In this case, individual VA culture and policies trump regional culture when explaining variation in screening practices.
Additionally, while many medical center characteristics are difficult to change, individual center policies, such as including PSA in routine labs, are highly amenable to change so they follow guidelines to involve patients in decisionmaking and reduce harm to the sickest patients. Aids to assist physicians assess life expectancy in elders may be useful to reduce screening in patients with limited life expectancy. 18, 42 Other tools, such as educational videos or pamphlets, may help physicians communicate with elders to guide decisions that will be best for patients' health. 43, 44 Furthermore, although performance measures have seen varied success, it may be useful to consider a new kind of measure that rewards physicians for not ordering a screening PSA when it is not appropriate, such as in the oldest and sickest men.
This study has several limitations. First, the study population was veterans, so results may not be generalizable outside the VA. Nevertheless, the VA is one of the largest healthcare systems for elderly men in the U.S., so understanding variations across the VA is important in its own right. Second, the rate of PSA screening at each VA reflects screening both in the community and at the VA, since these are not independent events; veterans who are screened using Medicare do not need a repeat test at a VA. To rule out that our findings were driven by community screening, we performed sensitivity analyses including only PSA tests within the VA; all associations remained the same. Third, data are from 2003 and may not reflect current screening practices. Nevertheless, a recent study indicates that annual PSA screening among men aged 75-79 remains high at 57% in 2005 and 2008. 45 Finally, because some PSA tests in the community may have been paid by sources other than Medicare, some screening may not be captured in our data. Thus, PSA screening among elderly veterans may in fact be higher than presented in this study.
In conclusion, PSA screening in veterans aged 70 and older with limited life expectancy varies greatly across VA medical centers with a threefold difference in screening between the highest and lowest screening VAs. These findings indicate the need for interventions to reduce inappropriate screening in elderly men, including efforts to change individual center practices that promote high screening regardless of life expectancy; PSA should not be included in routine labs. Additionally, guidelines and performance measures must do more to encourage individualized screening decisions that consider life expectancy. New communication tools are needed to help elderly men weigh benefits and harms of PSA screening, since current decision-aids focus on younger men. 43, 44 Initially, interventions should be directed at centers with high screening of men with limited life expectancy in order to minimize harms of screening. However, all VAs would benefit from these interventions because despite wide variation in PSA screening rates, medical centers are uniformly not targeting screening according to life expectancy.
